Pooled screening for CAR function identifies novel IL-13Rα2-targeted CARs for treatment of glioblastoma.

ABSTRACT:

Background

Chimeric antigen receptor (CAR) therapies have demonstrated potent efficacy in treating B-cell malignancies, but have yet to meaningfully translate to solid tumors. Nonetheless, they are of particular interest for the treatment of glioblastoma, which is an aggressive form of brain cancer with few effective therapeutic options, due to their ability to cross the highly selective blood-brain barrier.

Methods

Here, we use our pooled screening platform, CARPOOL, to expedite the discovery of CARs with antitumor functions necessary for solid tumor efficacy. We performed selections in primary human T cells expressing a library of 1.3×10⁶ third generation CARs targeting IL-13Rα2, a cancer testis antigen commonly expressed in glioblastoma. Selections were perform

SUBMITTER: Gordon KS 

PROVIDER: S-EPMC11815465 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature